Gocovri Approval History
FDA Approved: Yes (First approved August 24, 2017)
Brand name: Gocovri
Generic name: amantadine hydrochloride
Dosage form: Extended-Release Capsules
Previous Name: ADS-5102
Company: Adamas Pharmaceuticals, Inc.
Treatment for: Levodopa-Induced Dyskinesia
Gocovri (amantadine hydrochloride) is a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
Development History and FDA Approval Process for Gocovri
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.